Annual Cash & Cash Equivalents
$2.53 M
-$14.60 M-85.23%
December 31, 2023
Summary
- As of February 8, 2025, SLS annual cash & cash equivalents is $2.53 million, with the most recent change of -$14.60 million (-85.23%) on December 31, 2023.
- During the last 3 years, SLS annual cash & cash equivalents has fallen by -$32.77 million (-92.83%).
- SLS annual cash & cash equivalents is now -94.71% below its all-time high of $47.79 million, reached on December 31, 2013.
Performance
SLS Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Cash And Cash Equivalents
$21.03 M
+$11.88 M+129.92%
September 30, 2024
Summary
- As of February 8, 2025, SLS quarterly cash and cash equivalents is $21.03 million, with the most recent change of +$11.88 million (+129.92%) on September 30, 2024.
- Over the past year, SLS quarterly cash and cash equivalents has increased by +$18.50 million (+731.26%).
- SLS quarterly cash and cash equivalents is now -60.21% below its all-time high of $52.86 million, reached on March 31, 2015.
Performance
SLS Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash And Cash Equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
SLS Cash And Cash Equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -85.2% | +731.3% |
| 3 y3 years | -92.8% | +52.3% |
| 5 y5 years | -52.6% | +52.3% |
SLS Cash And Cash Equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -88.2% | at low | -22.1% | +731.3% |
| 5 y | 5-year | -92.8% | at low | -40.4% | +731.3% |
| alltime | all time | -94.7% | >+9999.0% | -60.2% | >+9999.0% |
SELLAS Life Sciences Cash And Cash Equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $21.03 M(+129.9%) |
| Jun 2024 | - | $9.15 M(-50.3%) |
| Mar 2024 | - | $18.41 M(+627.9%) |
| Dec 2023 | $2.53 M(-85.2%) | $2.53 M(-36.3%) |
| Sep 2023 | - | $3.97 M(-71.3%) |
| Jun 2023 | - | $13.81 M(-42.2%) |
| Mar 2023 | - | $23.90 M(+39.6%) |
| Dec 2022 | $17.13 M(-19.8%) | $17.13 M(-19.8%) |
| Sep 2022 | - | $21.35 M(-20.9%) |
| Jun 2022 | - | $26.99 M(+89.4%) |
| Mar 2022 | - | $14.25 M(-33.3%) |
| Dec 2021 | $21.36 M(-39.5%) | $21.36 M(-18.7%) |
| Sep 2021 | - | $26.28 M(-12.2%) |
| Jun 2021 | - | $29.92 M(+6.7%) |
| Mar 2021 | - | $28.03 M(-20.6%) |
| Dec 2020 | $35.30 M(+385.1%) | $35.30 M(+330.4%) |
| Sep 2020 | - | $8.20 M(+145.6%) |
| Jun 2020 | - | $3.34 M(-50.5%) |
| Mar 2020 | - | $6.75 M(-7.3%) |
| Dec 2019 | $7.28 M(+36.4%) | $7.28 M(-20.2%) |
| Sep 2019 | - | $9.12 M(-28.5%) |
| Jun 2019 | - | $12.75 M(+395.0%) |
| Mar 2019 | - | $2.58 M(-51.7%) |
| Dec 2018 | $5.34 M(+130.1%) | $5.34 M(-46.5%) |
| Sep 2018 | - | $9.97 M(+638.9%) |
| Jun 2018 | - | $1.35 M(-61.2%) |
| Mar 2018 | - | $3.47 M(+49.8%) |
| Dec 2017 | $2.32 M(-61.1%) | $2.32 M(-82.0%) |
| Sep 2017 | - | $12.91 M(-28.5%) |
| Jun 2017 | - | $18.07 M(-34.6%) |
| Mar 2017 | - | $27.64 M(+363.6%) |
| Dec 2016 | $5.96 M(-79.9%) | $5.96 M(-75.7%) |
| Sep 2016 | - | $24.51 M(+25.1%) |
| Jun 2016 | - | $19.59 M(-43.6%) |
| Mar 2016 | - | $34.71 M(+16.7%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $29.73 M(+25.7%) | $29.73 M(-14.6%) |
| Sep 2015 | - | $34.81 M(-23.1%) |
| Jun 2015 | - | $45.28 M(-14.3%) |
| Mar 2015 | - | $52.86 M(+123.5%) |
| Dec 2014 | $23.65 M(-50.5%) | $23.65 M(-4.0%) |
| Sep 2014 | - | $24.65 M(-37.1%) |
| Jun 2014 | - | $39.16 M(-25.3%) |
| Mar 2014 | - | $52.43 M(+9.7%) |
| Dec 2013 | $47.79 M(+45.7%) | $47.79 M(-7.0%) |
| Sep 2013 | - | $51.40 M(+145.7%) |
| Jun 2013 | - | $20.92 M(+19.7%) |
| Mar 2013 | - | $17.48 M(-46.7%) |
| Dec 2012 | $32.81 M(+187.0%) | $32.81 M(+112.7%) |
| Sep 2012 | - | $15.42 M(-19.8%) |
| Jun 2012 | - | $19.23 M(+121.0%) |
| Mar 2012 | - | $8.70 M(-23.9%) |
| Dec 2011 | $11.43 M(+65.9%) | $11.43 M(-27.1%) |
| Sep 2011 | - | $15.69 M(-12.5%) |
| Jun 2011 | - | $17.93 M(+61.3%) |
| Mar 2011 | - | $11.12 M(+61.3%) |
| Dec 2010 | $6.89 M(+21.2%) | $6.89 M(+143.0%) |
| Sep 2010 | - | $2.84 M(-44.3%) |
| Jun 2010 | - | $5.09 M(-65.7%) |
| Mar 2010 | - | $14.85 M(+161.3%) |
| Dec 2009 | $5.68 M(-42.3%) | $5.68 M(-36.8%) |
| Sep 2009 | - | $8.99 M(+106.1%) |
| Jun 2009 | - | $4.36 M(-39.2%) |
| Mar 2009 | - | $7.17 M(-27.2%) |
| Dec 2008 | $9.86 M(+459.0%) | $9.86 M(+169.0%) |
| Sep 2008 | - | $3.66 M(-59.4%) |
| Jun 2008 | - | $9.02 M(-8.5%) |
| Mar 2008 | - | $9.86 M(+459.1%) |
| Dec 2007 | $1.76 M(>+9900.0%) | $1.76 M(-25.1%) |
| Sep 2007 | - | $2.35 M(>+9900.0%) |
| Dec 2006 | $2000.00 | $2000.00 |
FAQ
- What is SELLAS Life Sciences annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for SELLAS Life Sciences?
- What is SELLAS Life Sciences annual cash & cash equivalents year-on-year change?
- What is SELLAS Life Sciences quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for SELLAS Life Sciences?
- What is SELLAS Life Sciences quarterly cash and cash equivalents year-on-year change?
What is SELLAS Life Sciences annual cash & cash equivalents?
The current annual cash & cash equivalents of SLS is $2.53 M
What is the all time high annual cash & cash equivalents for SELLAS Life Sciences?
SELLAS Life Sciences all-time high annual cash & cash equivalents is $47.79 M
What is SELLAS Life Sciences annual cash & cash equivalents year-on-year change?
Over the past year, SLS annual cash & cash equivalents has changed by -$14.60 M (-85.23%)
What is SELLAS Life Sciences quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of SLS is $21.03 M
What is the all time high quarterly cash and cash equivalents for SELLAS Life Sciences?
SELLAS Life Sciences all-time high quarterly cash and cash equivalents is $52.86 M
What is SELLAS Life Sciences quarterly cash and cash equivalents year-on-year change?
Over the past year, SLS quarterly cash and cash equivalents has changed by +$18.50 M (+731.26%)